Aurora kinase inhibitor-14
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia[1].
Product Specifications
CAS Number
958226-81-8
UNSPSC
12352005
Target
Apoptosis; Aurora Kinase
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(N(C)C1CCN(C)CC1)C2=CC=C(NC3=NC=C(C(F)(F)F)C(N[C@H]4C[C@@H](C(NC(C)C)=O)CC4)=N3)C=C2
Molecular Formula
C28H38F3N7O2
Molecular Weight
561.64
References & Citations
[1]Stephan Karl Zahn, et al. 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors. WO2007132010A1. 2007-11-22.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD50 / ICAM3 (CG106), CF640R conjugate, 0.1mg/mL
IgA Secretory Component (SC05), CF640R conjugate, 0.1mg/mL
IgA Secretory Component (SC05), CF568 conjugate, 0.1mg/mL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF405S conjugate, 0.1mg/mL
